Entera Bio

Contributing Author

Recent Articles by Entera Bio

6 hours	Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis ENTX GlobeNewswire
Feb-26	Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference ENTX GlobeNewswire
Feb-11	Entera Bio Announces Open Market Purchases of Company Stock by Board Members ENTX +13.10% GlobeNewswire
Feb-09	Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones ENTX +27.88% GlobeNewswire
Feb-04	OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism ENTX GlobeNewswire
Jan-21	Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook ENTX GlobeNewswire
Dec-23	Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation ENTX -6.38% GlobeNewswire
Dec-22	Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program) ENTX +6.21% GlobeNewswire
Nov-18	Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference ENTX GlobeNewswire
Nov-14	Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates ENTX GlobeNewswire
Oct-23	Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women ENTX -6.96% GlobeNewswire
Oct-16	Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting ENTX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.